menu search

PTCT / PTC Therapeutics (PTCT) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

PTC Therapeutics (PTCT) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
While the top- and bottom-line numbers for PTC Therapeutics (PTCT) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. Read More
Posted: Aug 3 2023, 22:31
Author Name: Zacks Investment Research
Views: 111693

PTCT News  

PTC Therapeutics, Inc. (PTCT) Q3 2023 Earnings Call Transcript

By Seeking Alpha
October 29, 2023

PTC Therapeutics, Inc. (PTCT) Q3 2023 Earnings Call Transcript

PTC Therapeutics, Inc. (NASDAQ:PTCT ) Q3 2023 Earnings Conference Call February 8, 2023 9:00 AM ET Company Participants Jane Hanlon - Associate Direct more_horizontal

Why Is PTC Therapeutics (PTCT) Stock Down 23% Today?

By InvestorPlace
October 27, 2023

Why Is PTC Therapeutics (PTCT) Stock Down 23% Today?

PTC Therapeutics (NASDAQ: PTCT ) stock is falling on Friday after the biopharmaceutical company released its earnings report for the third quarter of more_horizontal

PTC Therapeutics (PTCT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

By Zacks Investment Research
October 26, 2023

PTC Therapeutics (PTCT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

The headline numbers for PTC Therapeutics (PTCT) give insight into how the company performed in the quarter ended September 2023, but it may be worthw more_horizontal

Why PTC Therapeutics Soared 15% Higher Today

By The Motley Fool
October 19, 2023

Why PTC Therapeutics Soared 15% Higher Today

The biotech inked a lucrative royalty deal extension. Its counterparty is -- fittingly -- Royalty Pharma. more_horizontal

PTC Therapeutics stock jumps on royalty deal worth up to $1.5 billion

By Market Watch
October 19, 2023

PTC Therapeutics stock jumps on royalty deal worth up to $1.5 billion

PTC Therapeutics shares PTCT, -0.53% jumped 12% premarket on Thursday after the company announced a deal with Royalty Pharma PLC RPRX, -3.58% to monet more_horizontal

PTC Therapeutics (PTCT) Moves 5.3% Higher: Will This Strength Last?

By Zacks Investment Research
October 11, 2023

PTC Therapeutics (PTCT) Moves 5.3% Higher: Will This Strength Last?

PTC Therapeutics (PTCT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate more_horizontal

PTC Therapeutics (PTCT) to Cut 25% Jobs by January 2024

By Zacks Investment Research
September 29, 2023

PTC Therapeutics (PTCT) to Cut 25% Jobs by January 2024

PTC Therapeutics (PTCT) will reduce its workforce in accordance with its strategic prioritization process. It will also submit a re-examination reques more_horizontal

PTC Therapeutics announces job cuts to lower annual operating expenses

By Reuters
September 28, 2023

PTC Therapeutics announces job cuts to lower annual operating expenses

Drugmaker PTC Therapeutics said on Thursday it plans to cut workforce, which would impact about 25% of the organization, as it aims to reduce its year more_horizontal


Search within

Pages Search Results: